Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. (Q54232900)

26 May 2018

title

Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. (English)

1 reference

26 May 2018

author name string

J T Yarrington

1

1 reference

26 May 2018

J P Gibson

2

1 reference

26 May 2018

J E Dillberger

3

1 reference

26 May 2018

G Hurst

4

1 reference

26 May 2018

B Lippert

5

1 reference

26 May 2018

N M Sussman

6

1 reference

26 May 2018

W E Heydorn

7

1 reference

26 May 2018

R J Marler

8

1 reference

26 May 2018

language of work or name

English

0 references

publication date

1 September 1993

1 reference

26 May 2018

published in

Toxicologic Pathology

1 reference

26 May 2018

volume

21

1 reference

26 May 2018

issue

5

1 reference

26 May 2018

page(s)

480-489

1 reference

26 May 2018

Effects of vigabatrin on evoked potentials in dogs

cites work

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

The relationship between GABA concentrations in brain and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Analysis of the major amino acids of rat brain after in vivo inhibition of GABA transaminase by ethanolamine O-sulphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Neuropathology of vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

The effect of 4-amino hex-5-ynoic acid (gamma-acetylenic GABA, gammma-ethynyl GABA) a catalytic inhibitor of GABA transaminase, on brain GABA metabolism in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Enzyme-activated irreversible inhibition of rat and mouse brain 4-aminobutyric acid-alpha-ketoglutarate transaminase by 5-fluoro-4-oxo-pentanoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, ?-acetylenic GABA (4-amino-hex-5-ynoic acid) and ?-vinyl GABA (4-amino-hex-5-enoic acid)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

The pharmacology of GABA-transaminase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Vigabatrin: no microvacuoles in a human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA-transaminase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F019262339302100507

10.1177/019262339302100507

21 January 2018

Identifiers

DOI

1 reference

26 May 2018

PubMed ID

8115824

1 reference

26 May 2018